Table 2.
Vascular occlusive events by treatment allocation according to baseline risk.
| Baseline risk, n (%) | 0–5% |
6–10% |
11–20% |
>20% |
P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Tranexamic acid N=11 612 |
Placebo N=11 396 |
Tranexamic acid N=1245 |
Placebo N=1247 |
Tranexamic acid N=853 |
Placebo N=782 |
Tranexamic acid N=560 |
Placebo N=638 |
||
| Any vascular occlusive events | 64 (0.6) | 65 (0.6) | 17 (1.4) | 22 (1.8) | 23 (2.7) | 38 (4.9) | 14 (2.7) | 27 (4.2) | 0.255 |
| Fatal occlusive events | 16 (0.1) | 15 (0.1) | 6 (0.5) | 4 (0.3) | 4 (0.5) | 14 (1.8) | 1 (0.2) | 7 (1.1) | 0.058 |
| Myocardial infarction∗ | 8 (0.1) | 14 (0.1) | 3 (0.2) | 7 (0.6) | 6 (0.7) | 13 (1.7) | 7 (1.3) | 12 (1.9) | 0.909 |
| Stroke∗ | 19 (0.2) | 14 (0.1) | 3 (0.2) | 6 (0.5) | 6 (0.7) | 15 (1.9) | 4 (0.7) | 7 (1.1) | 0.152 |
| Pulmonary embolism∗ | 28 (0.2) | 23 (0.2) | 6 (0.5) | 8 (0.6) | 14 (1.6) | 16 (2.1) | 6 (1.1) | 9 (1.4) | 0.739 |
| Deep vein thrombosis∗ | 12 (0.1) | 19 (0.2) | 7 (0.6) | 2 (0.2) | 6 (0.7) | 4 (0.5) | 3 (0.5) | 5 (0.8) | 0.214 |
∗
Includes both fatal and non-fatal events.